Early access
Sign in
Taking peopleNo phase

Blood clotting drug levels and clots in intensive care patients

Looks at enoxaparin blood levels and clots in adults in intensive care.

Key facts

Who runs it
Medical University of Vienna
Where
Austria3 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients
Status
Recruiting
People taking part
1,300 people, planned
Started
4 May 2024
Expected to end
Aug 2027
Type of study
Observational
Treatments tested
  • Anti-factor Xa activity calibrated for enoxaparin
Record updated
23 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults admitted to an intensive care unit in the last 24 hours. It studies how a blood test (anti-factor Xa activity) relates to blood clots in veins and lungs.

Age
Over 18 years at the time of intensive care unit admission
Sex
All sexes
Disease stage
Critically ill patients admitted to a participating intensive care unit within the last 24 hours. Expected to stay more than 48 hours after joining.
Earlier treatment
People cannot join if they get full-strength blood thinning: enoxaparin of at least 100 IE/kg twice daily or at least 150 IE/kg once daily.

Main reasons for not taking part

  • Planned regular use of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors
  • Heart-lung machine support (extracorporeal membrane oxygenation) in place or planned within 48 hours
  • Expected to live less than 48 hours, or on comfort care at end of life
  • Earlier diagnosis of heparin-induced thrombocytopenia (low platelets caused by heparin)
  • Admitted before a planned surgery, or already in this study before

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age over 18 years at the time of intensive care unit admission
  • Admission to a participating intensive care unit within the last 24 hours
  • Expected discharge is later than 48 hours after enrolment

Who cannot take part

  • Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period
  • Previously diagnosed heparin-induced thrombocytopenia
  • Pre-operative admission for elective surgery
  • Previous enrolment in the study
  • Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE/kg when given twice daily or of at least 150 IE/kg when given once daily
  • Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment
  • Estimated life expectancy below 48 hours or comfort terminal care order in place

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:

Read full original descriptionShow less

* What is the association between antiXa and VTE? * What is the association between antiXa and symptomatic, respectively incidental, VTE? * How is pharmacological anticoagulation with enoxaparin related to measured antiXa? * What is the association between antiXa and bleeding complications. * What is the incidence of venous thromboembolism in patients treated at an intensive care unit? * How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit/hospital.

The group in the trial

  • Intensive care unit patients

    Patients who are admitted to an participating intensive care unit who do not receive therapeutic anticoagulation.

    Treatment: Anti-factor Xa activity calibrated for enoxaparin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study
Plain-language title
Blood clotting drug levels and clots in intensive care patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
23 June 2026